Gene patents still alive and kicking: their impact on provision of genetic testing for long QT Syndrome in the Canadian Public Healthcare System. Genetics in Medicine. doi:10.1038/gim.2017.43

PRM30-Should decision makers embrace non-constant discounting? Value in Health.

Rare Diseases and Resource Allocation Policy: The Role of Canadian Legal Norms. UBC Law Review

The direct-to-consumer genetic testing fog. Policy Options

Show drugs work before selling them. Nature.

Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLoS Biology.

Consider drug efficacy before first-in-human trials. Nature.

Human gene editing: revisiting Canadian policy. Regenerative Medicine.

A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models. SpringerLink.

Prehospital randomised assessment of a mechanical compression device in out-of-hospital cardiac arrest (PARAMEDIC): a pragmatic, cluster randomised trial and economic evaluation. Health Technology Assessment. National Institute for Health Research.

Marketing of unproven stem cell-based interventions: A call to action. Science Translational Medicine.

Long-term Results from the Empowering a Multimodel Pathway Toward Health Youth Program, a Multimodel School-Based Approach, Show Marked Reductions Suicidality, Depression, and Anxiety in 6,227 Students in Grades 6-12 (Aged 11-18). Frontiers in Psychiatry.  NCBI.


Accelerating Translational Research through Open Science: The Neuro Experiment. PLoS Biology.

The health economics for regenerative medicine: how payers think and what that means for developers. Mesenchymal Stromal Cells: Translational Pathways to Clinical Adoption.

Rare diseases and resource allocation policy: the role of Canadian legal and ethical norms. UBC Law Review.

Cancer Drugs Fund 2.0: A Missed Opportunity? Pharmacoeconomics.

Precision medicine: drowning in a regulatory soup? Journal of Law and the Biosciences

Controversies with Kalydeco: newspaper coverage and the United States of the cycstic fibrosis “wonder drug”. Journal of Cystic Fibrosis

Media portrayal of non-invasive prenatal testing: a missing ethical dimension. Journal of Clinical Outcomes Management

The Mouse that Trolled (Again). Journal of Law and the Biosciences

Cell therapy licensing: a web for the unwary in Kimble v. Marvel Entertainment? Regenerative Medicine.

Choroideremia Research Report and Perspectives on the Second International Scientific Symposium for Choroideremia. Ophthalmic Genetics.

Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines. Stem cell Reports. Cell Press.

Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine. SpringerLink.

Determinants of Change in the Cost-effectiveness Threshold. Medical Decision Making. SAGE Journals.

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. Journal of the National Cancer Institute. Oxford University Press.

Cost effectiveness and value of information analyses of islet cell transplantation in the management of ‘unstable’ type 1 diabetes mellitus. BMC endocrine disorders. BioMed Central Ltd.

One-year resource allocation, utilisation, costs and quality of life in patients with acute respiratory distress syndrome (ARDS): secondary analysis of a randomised controlled trial. Journal of Intensive Care Medicine. BioMed Central.

Undertested and Overpriced: Japan Issues First Conditional Approval of Stem Cell Product. Cell Stem Cell. Elsevier


Innovating a Canadian innovation ecosystem. Policy Options.

The media and access issues: content analysis of Canadian newspaper coverage of health policy decisions. Orphanet Journal of Rare Diseases.

The gene patent controversy on Twitter: a case study of Twitter users’ responses to the CHEO lawsuit against Long QT gene patents. BMC Medical Ethics.

The commercialization of university-based research: Balancing risks and benefits. BMC Medical Ethics.

Marginally Scientific? Genetic Testing of Children and Adolescents for Lifestyle and Health Promotion. Journal of Law and the Biosciences.

Current Practices and Reform Proposals for the Regulation of Advanced Medicinal Products in Canada. Regenerative Medicine.

The Obesity Gene and the (Misplaced) Search for a Personalized Approach to Our Weight Gain Problems. Wake Forest Journal of Law and Policy

Commercialisation of Human Genetic Research. Encyclopedia of Life Sciences.

Use and Misuse of Material Transfer Agreements: Lessons from Research, Repositories, and Litigation. PLoS Biology

Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. Regenerative medicine. Future Medicine Ltd.

Use of Bayesian Markov Chain Monte Carlo Methods to Estimate EQ-5D Utility Scores from EORTC QLQ Data in Myeloma for Use in Cost-Effectiveness Analysis. Medical Decision making. Sage.

The use of early decision making and value of information analysis in an adaptive trial design results from the OPTIMA preliminary study. Trials. BioMed Central Ltd.

Self-Harm Intervention: Family Therapy (SHIFT), a study protocol for a randomised controlled trial of family therapy versus treatment as usual for young people seen after a second or subsequent episode of self-harm. Trials. BioMed Central Ltd.

Pressure Ulcer Programme of Research: using mixed methods to identify patient and organisational risk, develop a risk assessment tool and patient-reported outcome Quality of Life and Health Utility measures. NIHR Journals Library. NIHR.


Theory Testing and Implication in Clinical Trials. Philosophy of Science.

Are Outcome-Adaptive Allocation Trials Ethical? Clinical Trials.

Physician Liability and Non-Invasive Prenatal Testing. J Obstet Gynaecol Can.

Science Powers Commerce: Mapping the Language, Justifications, and Perceptions of the Drive to Commercialize in the Context of Canadian Research. Canadian Journal of Comparative and Contemporary Law

Newspaper Coverage of Biobanks. Peer J.

Defining medical necessity in an age of personalised medicine: A view from Canada. Bioessays.

It’s not all in the genes. Policy Options.

Direct to Consumer Genetic Testing in Canada: should we be concerned. Healthy Debate.

Some Inconsistencies in NICE’s Consideration of Social Values. Pharmacoeconomics.

Determining social values for resource allocation decision-making in cancer care: a Canadian experiment. Journal of Cancer Policy.

Value-Engineered Translation: Developing Biotherapeutics that align with health-system needs. American Journal of Managed Care: Evidence-Based Diabetes Management 20 (Special Issue 10).

Should patients be told about incidental findings from genetic testingHealthy Debate.

The Right to Control and Access Genetic Material: Does McInerney Offer a Way Out of the Consent/Withdrawal Conundrum? UBC Law Review.

Methods for Identifying the Cost-effective Case Definition Cut-Off for Sequential Monitoring Tests: An Extension of Phelps and Mushlin. PharmacoEconomics.

Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice? PharmacoEconomics

Human genetic research, race, ethnicity and the labeling of populations: recommendations based on an interdisciplinary workshop in Japan. BMC Medical Ethics.

Methods for Identifying the Cost-effective Case Definition Cut-Off for Sequential Monitoring Tests: An Extension of Phelps and Mushlin. PharmacoEconomics.

Policy recommendations for addressing privacy challenges associated with cell-based research and interventions. BMC Medical Ethics.


Reflections on the Cost of “Low-Cost” Whole Genome Sequencing: Framing the Health Policy Debate. PLoS Biology.

Value-Engineered Translation for Regenerative Medicine: Meeting the Needs of Health Systems. Stem Cells and Development.

The Paradoxes of Pop Science. Policy Options. Sept – Oct 2013

Pressing the Pause Button. Cure Magazine. Sept 2013

Direct-to-consumer genetic testing — where should we focus the policy debate? Medical Journal of Australia.

Reflections on the Cost of “Low-Cost” Whole Genome Sequencing: Framing the Health Policy Debate. PLoS Biology.

Ethics and Genomic Incidental Findings. Science.

Policy Uncertainty, Sequencing, and Cell Lines. G3 Genomes.

Angelina Jolie’s faulty gene: newspaper coverage of a celebrity’s preventive bilateral mastectomy in Canada, the United States, and the United Kingdom. Genetics in Medicine.

A Canadian screening program for hepatitis C: Is now the time? CMAJ online